Filters
Any expectations from the more powerful dulaglutide?
Dulaglutide is a frequently used GLP-1 analogue and one of the most potent antidiabetic drugs. Practical aspects of treatment with dulaglutide are presented in this article, together with new data from AWARD-11 study with higher con...
Endocrinology and metabolism (including diabetes, hormones)
- 2022 •
- JSC •
- Link
Rok uplatnění
JSC - Článek v periodiku v databázi SCOPUS
Výsledek na webu
Dulaglutide
Dulaglutide is a GLP-1 receptor agonist administered in a subcutaneous injection once weekly using prefilled injector. It is used for the treatment of adult, positive effects of dulaglutide also include body weight and blood pressur...
Endocrinology and metabolism (including diabetes, hormones)
- 2018 •
- Jost •
- Link
Rok uplatnění
Jost - Ostatní články v recenzovaných periodicích
Výsledek na webu
Possibilities to improve glycemic control in DM type 2 and dulaglutide
The article in the journal Profi medicína entitled: Possibilities to improve glycemic control in type 2 DM and dulaglutide.
Endocrinology and metabolism (including diabetes, hormones)
- 2019 •
- Jost •
- Link
Rok uplatnění
Jost - Ostatní články v recenzovaných periodicích
Výsledek na webu
Dulaglutid
Dulaglutide is a new long-acting glucagon-like peptide-1 receptor agonist (GLP plasmatic concentration is being reached after 2-4 weeks of application. Dulaglutide blood pressure (by -2.8 mm Hg). Effectiveness and safety of dula...
FB - Endokrinologie, diabetologie, metabolismus, výživa
- 2016 •
- Jx
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Once-Daily Liraglutide in Patients with Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRation
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Once-Daily Liraglutide in Patients with Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRation of LY2189265 in Diabetes-6). A Study of <...
FB - Endokrinologie, diabetologie, metabolismus, výživa
- 2014 •
- Vsouhrn
Rok uplatnění
Vsouhrn - Souhrnná výzkumná zpráva
Dulaglutide as an Alternative for Short-Acting Insulin in Type 2 Diabetes Treatment
The case study reffers to the patient with both type 2 diabetes mellitus and secondary diabetes due to corticosteroid treatment. The decline of renal function lead to intensified insulin therapy. After stabilization of nefropathy, a successfull switc...
Endocrinology and metabolism (including diabetes, hormones)
- 2020 •
- Jost •
- Link
Rok uplatnění
Jost - Ostatní články v recenzovaných periodicích
Výsledek na webu
Dulaglutide and Incident Atrial Fibrillation or Flutter in patients with type 2 Diabetes; a post-hoc analysis from the REWIND Randomized Trial
weekly subcutaneous dulaglutide vs placebo in the REWIND study. MATERIALS AND METHODS. Additional analyses included whether dulaglutide compared to placebo reduced to dulaglutide (5.6%), at a rate of 10.7 per 1000 person-y...
Cardiac and Cardiovascular systems
- 2022 •
- Jimp •
- Link
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
the effect of the GLP-1 receptor agonist dulaglutide on major adverse cardiovascular injection of dulaglutide (1.5 mg) or placebo. Randomisation was done by a computer dulaglutide (n=4949) or placebo (n=4952). During a med...
Cardiac and Cardiovascular systems
- 2019 •
- Jimp •
- Link
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
Dulaglutide and Cardiovascular and Heart Failure Outcomes in Patients With and Without Heart Failure: A Post-hoc Analysis from the REWIND Randomized Trial
dulaglutide on incident heart failure events and other cardiovascular outcomes in those assigned to dulaglutide and 226/4952 (4.6%) participants assigned to placebo failure events with dulaglutide as compared to participan...
Cardiac and Cardiovascular systems
- 2022 •
- Jimp •
- Link
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model
formulations of the antipsychotic olanzapine and the GLP-1 RA dulaglutide for 8 days. A pair-feeding protocol evaluated the combined effects of dulaglutide and food but not serum markers. Dulaglutide led to a modest decrea...
Pharmacology and pharmacy
- 2024 •
- Jimp •
- Link
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
- 1 - 10 out of 19